Hemab Therapeutics (NASDAQ:COAG – Get Free Report) was upgraded by investment analysts at Jefferies Financial Group to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports.
Several other equities research analysts have also issued reports on COAG. The Goldman Sachs Group began coverage on shares of Hemab Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $36.00 price objective for the company. Evercore began coverage on shares of Hemab Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $50.00 price objective for the company. Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Finally, Wedbush began coverage on shares of Hemab Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $42.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating and two have issued a Buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Strong Buy” and an average target price of $41.75.
View Our Latest Analysis on Hemab Therapeutics
Hemab Therapeutics Stock Up 7.5%
Hemab Therapeutics (NASDAQ:COAG – Get Free Report) last released its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.
Insiders Place Their Bets
In other news, major shareholder Ra Capital Management, L.P. purchased 3,802 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was acquired at an average cost of $24.97 per share, with a total value of $94,935.94. Following the acquisition, the insider owned 6,375,972 shares in the company, valued at approximately $159,208,020.84. This trade represents a 0.06% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders have acquired 2,902,872 shares of company stock worth $53,769,784.
Hemab Therapeutics Company Profile
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.
Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.
Further Reading
- Five stocks we like better than Hemab Therapeutics
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Receive News & Ratings for Hemab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
